Halozyme Therapeutics, Inc.
Could not find a ticker for this position, may be a filing error
A San Diego biopharma company whose ENHANZE technology uses a naturally occurring enzyme to temporarily loosen the gel-like tissue under the skin, letting large-volume biologic medicines be injected in minutes instead of slowly dripped over hours. Its partners sell drugs built on this platform, such as DARZALEX FASPRO and HYQVIA, and it also makes auto-injector devices and its own products like XYOSTED. Co-founded in 1998 by Dr. Gregory Frost, the company's name blends "hyaluronidase" and "enzyme" — the very molecule its science revolves around.
Senior unsecured convertible notes due March 1, 2027
Granted 1.72M · Sold 1.14M
Granted 20.8K · Sold 32.0K
Granted 465.6K · Sold 387.0K
Granted 28.7K · Sold 79.9K
Granted 14.3K
Granted 103.7K
Granted 31.7K · Sold 14.1K
Granted 149.8K · Sold 64.8K
Granted 28.7K · Sold 45.0K
Granted 24.9K
Granted 23.7K
Granted 14.3K · Sold 20.0K
Granted 6.9K
Granted 33.5K · Sold 33.1K
Granted 21.8K · Sold 7.3K
Granted 4.7K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Torley HelenPRESIDENT AND CEO, Director · 259 transactions | +43.5% | 773.9K | 1.72M | — | 1.14M |
| Matsui ConnieDirector · 7 transactions | -14.5% | 183.0Kas of Nov 2024 | 20.8K | — | 32.0K |
| LaBarre Michael J.SVP, CHIEF TECHNICAL OFFICER · 132 transactions | +16.8% | 173.8Kas of Feb 2025 | 465.6K | — | 387.0K |
| Posard Matthew L.Director · 13 transactions | -39.7% | 77.8K | 28.7K | — | 79.9K |
| Bizzari Jean-PierreDirector · 2 transactions | +27.2% | 66.8Kas of May 2023 | 14.3K | — | — |
| Snyder Mark HowardSVP, CHIEF LEGAL OFFICER · 28 transactions | — | 52.6K | 103.7K | — | — |
| Connaughton BernadetteDirector · 16 transactions | +36.4% | 43.7K | 31.7K | — | 14.1K |
| LaBrosse NicoleSVP, CHIEF FINANCIAL OFFICER · 62 transactions | — | 42.1K | 149.8K | — | 64.8K |
| Henderson Jeffrey WilliamDirector · 15 transactions | -30.8% | 36.6K | 28.7K | — | 45.0K |
| Miyashita Akiko MoniDirector · 4 transactions | — | 24.9Kas of May 2025 | 24.9K | — | — |
| Duncan Barbara GayleDirector · 5 transactions | — | 23.7K | 23.7K | — | — |
| Daly James MDirector · 4 transactions | -21.8% | 20.5Kas of Aug 2023 | 14.3K | — | 20.0K |
| Matsuda MasaruSVP, General Counsel · 2 transactions | +20.9% | 20.0Kas of Sep 2021 | 6.9K | — | — |
| Caudill CortneySVP, CHIEF OPERATING OFFICER · 9 transactions | — | 15.9K | 33.5K | — | 33.1K |
| Krishnan MaheshDirector · 5 transactions | — | 14.5K | 21.8K | — | 7.3K |
| Lang James PaulDirector · 2 transactions | — | 4.7K | 4.7K | — | — |
Select a row to see that insider’s individual transactions.
Net open-market activity over the last 5 years: -1.82M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.